Navigation Links
Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer
Date:1/26/2012

Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

Erlotinib is an oral anti-cancer drug that can slow a tumor's growth and spread by inhibiting specific growth receptors on the surface of the cancer cells. Early detection of a patient's response to EGFR inhibitors, such as erlotinib, is critical to personalizing head and neck cancer treatments.

In a first of its kind study in patients with head and neck cancer, researchers sought to determine how well tumors unaffected by other therapies respond to erlotinib, when the drug dose was adjusted according to the patient's smoking status. It has been recently shown that smokers metabolize the drug faster than nonsmokers.

Nonsmokers received 150 mg per day and smokers received 300 mg per day for at least 14 days before surgery. A FDG-PET scan and neck CT was performed before treatment and at the end of erlotinib administration. In addition, an early FDG-PET was performed after four to six days of treatment.

The results showed that erlotinib is effective as a first line of therapy when the dose is adjusted per smoking status, even when used for a limited duration. Both smokers and nonsmokers tolerated the dose of erlotinib and neither experienced serious adverse effects. The study also showed that the FDG-PET scan taken early can show changes in the standard uptake value and predict a patient's response to erlotinib.

"We hope our results will motivate clinicians to consider and investigate further the use of erlotinib in patients with head and neck cancer and adjust the dose for smoking status," Mercedes Porosnicu, MD, lead author of the study and an assistant professor of internal medicine at Wake Forest Baptist Medical Center in Winston Salem, N.C., said. "We also hope that our study will help better select the patients expected to respond to erlotinib."


'/>"/>
Contact: Nicole Napoli
nicolen@astro.org
703-839-7336
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Blood test may identify lung cancer patients likely to respond to erlotinib
2. TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer
3. Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
4. PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
5. EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
6. New Report: $1 Cigarette Tax Increase Would Raise $418.8 Million for Texas and Cut Youth Smoking
7. New Report: $1 Cigarette Tax Increase Would Raise $18.6 Million for Montana and Cut Youth Smoking
8. New Report: $1 Cigarette Tax Increase Would Raise $24.8 Million for Wyoming and Cut Youth Smoking
9. New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking
10. New Report: $1 Cigarette Tax Increase Would Raise $113.9 Million for Colorado and Cut Youth Smoking
11. New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at the Renaissance ... program. , An attendee at a recent PAINWeekEnd said, "Very helpful, wish we ... entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by Dr. Ted ...
(Date:4/24/2017)... Calif. (PRWEB) , ... April 24, 2017 , ... Donna ... topics, but she has not found any of them to be very practical. She ... to slowly and easily make changes in their health. It prompted her in writing ...
(Date:4/24/2017)... ... 2017 , ... “Reflections of God’s Work”: an enlightening collection of life lessons ... creation of published author, Jerri Broglin, a survivor of great loss who gained insight ... great eye-opener for those searching for answers, as we are finding the answers that ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Life of Purpose ... of Florida. The event will be held at 7:30 pm on May 10th at ... and Drew Copeland of Sister Hazel, will support the UF Collegiate Recovery Community (UFCRC). ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... 18, 2017  Astute Medical, Inc., developer of biomarkers ... be presented at the 2017 National Kidney Foundation (NKF) ... continues through April 22. Physicians will present data on ... assess risk for acute kidney injury (AKI) during the ... Elevated levels of TIMP-2 and IGFBP-7 ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext ... of collaboration started in 2016, in which Socionext ... Brain SOINN". The companies achieved initial results in ... solution by Artificial Brain SOINN. The results will ... Big Sight, April 19-21, at booths 4505 & ...
(Date:4/18/2017)... April 18, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... of bacterial infections, will present preclinical data supporting the ... multidrug resistant (MDR) Gram-negative infections at the 27th European ... 22-25, 2017 in Vienna, Austria . ... "Our ...
Breaking Medicine Technology: